During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), to be held May 31st – June 4th, 2024, expect to see major presentation of data across Bristol Myers Squibb (BMS)’s oncology and hematology portfolio including data from more than 130 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning approximately 25 cancer types and serious blood disorders.
“At this year’s ASCO, we have the opportunity to share data across our robust and differentiated oncology portfolio including new data from pivotal studies, data that reinforce the longer-term impact our medicines are having for patients, and emerging science in the oncology space,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, Bristol Myers Squibb/BMS.
“We are focused on advancing critical research across immuno-oncology, targeted therapy, protein degradation, cell therapy, and radiopharmaceutical therapy, all with the goal of delivering potentially transformative treatment options that help provide long-term benefit for patients,” Hirawat added.
Key data being presented by Bristol Myers Squibb at ASCO include:
New pivotal data
- Progression-free survival and overall response rate data from the Phase 3 KRYSTAL-12 study (NCT04685135) evaluating adagrasib (Krazati® ; Bristol Myers Squibb/BMS) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
- First disclosure of results from the Phase 3 CheckMate -9DW trial (NCT04039607) demonstrating overall survival benefit with nivolumab (Opdivo®; Bristol Myers Squibb/BMS ) plus ipilimumab (Yervoy®; Bristol Myers Squibb/BMS) vs. investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with advanced hepatocellular carcinoma (aHCC).
Executive Vice President, Chief Medical Officer, Drug Development As chief medical officer, Drug Development, Samit Hirawat, MD, oversees early-stage and late-stage product development across all therapeutic areas. In this role, Samit and his organization focus on enabling the rapid progression and delivery of assets, from proof-of-concept to commercialization, through world-class clinical trial design and operations. Photo Courtesy © 2024 Bristol Myers Squibb/BMS. Used with permission,Data strengthening the profile of our existing portfolio
- Three-year follow-up data from the Phase 3 RELATIVITY-047 study (NCT03470922) demonstrating sustained responses with nivolumab and relatlimab (Opdualag™; Bristol Myers Squibb/BMS) in previously untreated metastatic or unresectable melanoma.[1]
- Five-year data from the Phase 3 CheckMate-9LA (NCT03215706) trial showing favorable clinical outcomes and durable survival benefit in patients with metastatic NSCLC treated with nivolumab plus ipilimumab with chemotherapy vs. chemotherapy.
- Four-year follow-up data from the Phase 3 CheckMate-816 trial (NCT02998528) reinforcing neoadjuvant nivolumab plus chemotherapy as a treatment in resectable NSCLC.[2]
- Exploratory analysis from the Phase 3 CheckMate-77T trial (NCT04025879) supporting the potential use of a perioperative nivolumab-based regimen as a treatment option for patients with resectable NSCLC, regardless of nodal status.[3]
- Multiple subgroup analyses from the Phase 1/2 TRANSCEND CLL 004 (NCT03331198) , Phase 1 TRANSCEND NHL 001 (MCL cohort; NCT02631044) and Phase 2 TRANSCEND FL studies (NCT04245839)reinforcing the deep and durable responses with lisocabtagene maraleucel (Breyanzi®; Bristol Myers Squibb/BMS), demonstrating consistent clinical outcomes in relapsed/refractory chronic lymphocytic leukemia (CLL), relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory follicular lymphoma (FL) across a broad study population.
Emerging science
- Efficacy and safety data from the Phase 2/3 RELATIVITY-048 (NCT03459222) trial evaluating the triplet combination of nivolumab, relatlimab, and ipilimumab in patients with advanced melanoma. Although the study demonstrates promising response rates and survival outcomes in patients, these results require confirmation in larger randomized trials,
- Safety and efficacy data from the Phase 1b portion of the ACTION-1 trial (NCT05477576) of RYZ101 (an alpha-emitting radiopharmaceutical in development for SSTR2+ solid tumors) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy.
- New Phase 1/2 data from the targeted protein degradation platform including the novel oral CELMoD agents iberdomide in newly diagnosed multiple myeloma, mezigdomide in relapsed/refractory multiple myeloma, and golcadomide in first-line LBCL and relapsed/refractory FL, reinforcing promising activity.
Select Bristol Myers Squibb studies at the 2024 ASCO Annual Meeting include:
Abstract Title | Author | Presentation Type/# | Session Title | Session Date/Time (CDT) |
Acute Myeloid Leukemia (AML) | ||||
A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study. | Stéphane De Botton | Poster Abstract #6522 | Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Bladder Cancer | ||||
SOGUG-Vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer. | Guillermo De Velasco | Poster Abstract #4576 | Genitourinary Cancer—Kidney and Bladder | Sunday, June 2, 2024 9:00 AM – 12:00 PM |
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial. | Matthew D. Galsky | Oral Abstract #4509 | Genitourinary Cancer—Kidney and Bladder | Monday, June 3, 2024 8:00 AM – 11:00 AM |
Breast Cancer | ||||
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd). | Mark Pegram | Poster Abstract #TPS1121 | Breast Cancer—Metastatic | Sunday, June 2, 2024 9:00 AM – 12:00 PM |
Chronic Lymphocytic Leukemia (CLL) | ||||
Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT). | Lin Wang | Poster Abstract #7046 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Association between treatment (tx) response and PFS and OS in R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A 12-month landmark (LM) meta-analysis. | Xin Wang | Poster Abstract #7047 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Colorectal Cancer (CRC) | ||||
A phase 2 study evaluating response and biomarkers in patients with microsatellite stable (MSS) advanced colorectal cancer (CRC) treated with nivolumab/relatlimab. | Eric Christenson | Poster Abstract #3554 | Gastrointestinal Cancer—Colorectal and Anal | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. | Heinz-Joseph Lenz | Oral Abstract #3503 | Gastrointestinal Cancer—Colorectal and Anal | Sunday, June 2, 2024 8:00 AM – 11:00 AM |
Esophageal Cancer (EC) and Gastrointestinal Cancers | ||||
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648. | Ian Chau | Poster Abstract #4034 | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. | Elena Elimova | Poster Abstract #4040 | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649). | Daniel Lin | Poster Abstract #4044 | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). | Jennifer Rachel Eads | Oral Abstract #4000 | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Tuesday, June 4, 2024 9:45 AM – 12:45 PM |
Hepatocellular Carcinoma (HCC) | ||||
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. | Peter Robert Galle | Oral Abstract #LBA4008 | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Tuesday, June 4, 2024 9:45 AM – 12:45 PM |
Melanoma | ||||
Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. | Paolo Antonio Ascierto | Oral Abstract #9504 | Melanoma/Skin Cancers | Friday, May 31, 2024 2:45 PM – 5:45 PM |
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years. | Hussein A. Tawbi | Poster Abstract #9524 | Melanoma/Skin Cancers | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC). | Dirk Schadendorf | Poster Abstract #9557 | Melanoma/Skin Cancers | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment. | Michael A. Postow | Poster Abstract #9539 | Melanoma/Skin Cancers | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma. | Steven Y. Liu | Poster Abstract #TPS9619 | Melanoma/Skin Cancers | Saturday, June 1, 2024 1:30 PM – 4:30 PM |
Multiple Myeloma (MM) | ||||
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3. | Bertrand Arnulf | Poster Abstract #7527 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM). | Suzanne Trudel | Poster Abstract #7539 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3. | Clara Amorosi | Poster Abstract #7529 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Myelodysplastic Syndromes (MDS) | ||||
Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial. | Guillermo Garcia-Manero | Rapid Oral Abstract #6509 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Saturday, June 1, 2024 8:00 AM – 9:30 AM |
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)-naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial. | Amer Methqal Zeidan | Poster Abstract #6565 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Non-Hodgkin Lymphoma (includes DLBCL, LBCL, FL, MCL, etc.) | ||||
Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL). | M. Lia Palomba | Rapid Oral Abstract #7016 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Sunday, June 2, 2024 4:30 PM – 6:00 PM |
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. | Manali Kirtikumar Kamdar | Rapid Oral Abstract #7013 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Sunday, June 2, 2024 4:30 PM – 6:00 PM |
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). | Allison Marie Winter | Rapid Oral Abstract #7010 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Sunday, June 2, 2024 4:30 PM – 6:00 PM |
Impact of clinical response and AEs on health-related quality of life (HRQoL) in patients (pts) with R/R large B-cell lymphoma (LBCL): Pooled data from 4 lisocabtagene maraleucel (liso-cel) trials. | Patrick Connor Johnson | Poster Abstract #11105 | Quality Care/Health Services Research | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Estimating the health care costs associated with receipt of lisocabtagene maraleucel: Insights from adults with mantle cell lymphoma (TRANSCEND NHL 001). | Tycel Jovelle Phillips | Poster Abstract #7028 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL). | M. Lia Palomba | Poster Abstract #7068 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP). | Mecide Meric Gharibo | Poster Abstract #7026 | Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia | Monday, June 3, 2024 9:00 AM – 12:00 PM |
Non-Small Cell Lung Cancer (NSCLC) | ||||
KRYSTAL-12: Phase 3 Study of Adagrasib versus Docetaxel in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring a KRASG12C Mutation. | Tony Mok | Oral Abstract #LBA8509 | Clinical Science Symposium—Targeting KRAS in Non-Small Cell Lung Cancer | Saturday, June 1, 2024 1:15 PM – 2:45 PM |
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. | Jonathan Spicer | Rapid Oral Abstract #LBA8010 | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | Sunday, June 2, 2024 4:30 PM – 6:00 PM |
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study. | Tina Cascone | Oral Abstract #LBA8007 | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | Monday, June 3, 2024 8:00 AM – 11:00 AM |
Correlation of the combination of CT-derived tumor texture and vessel tortuosity on survival outcomes for immunotherapy but not for chemotherapy in metastatic non-small cell lung cancer (mNSCLC): Results from a CheckMate227 (CM227) subset. | Pushkar Mutha | Poster Abstract #8610 | Lung cancer—Non-Small Cell Metastatic | Monday, June 3, 2024 1:30 PM – 4:30 PM |
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. | Martin Reck | Poster Abstract #8560 | Lung cancer—Non-Small Cell Metastatic | Monday, June 3, 2024 1:30 PM – 4:30 PM |
Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies. | Alexander Drilon | Poster Abstract #8522 | Lung cancer—Non-Small Cell Metastatic | Monday, June 3, 2024 1:30 PM – 4:30 PM |
Pancreatic Cancer | ||||
Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings. | Daniel Halperin | Poster Abstract #3091 | Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | Saturday, June 1, 2024
9:00 AM – 12:00 PM |
Renal Cell Carcinoma (RCC) | ||||
Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial. | Saby George | Poster Abstract #4535 | Genitourinary Cancer—Kidney and Bladder | Sunday, June 2, 2024 9:00 AM – 12:00 PM |
Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial. | Maria T. Bourlon | Poster Abstract #4532 | Genitourinary Cancer—Kidney and Bladder | Sunday, June 2, 2024 9:00 AM – 12:00 PM |
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial. | Sayed Matar | Poster Abstract #4536 | Genitourinary Cancer— Kidney and Bladder | Sunday, June 2, 2024 9:00 AM – 12:00 PM |
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC). | Charlene Mantia | Oral Abstract #4507 | Genitourinary Cancer—Kidney and Bladder | Monday, June 3, 2024 8:00 AM – 11:00 AM |
Brain Cancer | ||||
Phase II study of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors. | Elisabetta Xue | Poster #TPS3183 | Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | Saturday, June 1, 2024 9:00 AM – 12:00 PM |
Clinical trials
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) – ClinicalTrials.gov ID NCT04685135
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) – ClinicalTrials.gov ID NCT04039607
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047) – ClinicalTrials.gov ID NCT03470922
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) – ClinicalTrials.gov ID NCT03215706
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) – ClinicalTrials.gov ID NCT02998528
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer ClinicalTrials.gov ID NCT04025879
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) ClinicalTrials.gov ID NCT03331198
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) ClinicalTrials.gov ID NCT02631044
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) ClinicalTrials.gov ID NCT04245839
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread – ClinicalTrials.gov ID NCT03459222
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) ClinicalTrials.gov ID NCT05477576
Highlights of Prescribing Information
Adagrasib (Krazati® ; Bristol Myers Squibb/BMS)[Prescribing Information]
Nivolumab (Opdivo®; Bristol Myers Squibb/BMS ) [Prescribing Information]
Ipilimumab (Yervoy®; Bristol Myers Squibb/BMS) [Prescribing Information]
Nivolumab and relatlimab (Opdualag™; Bristol Myers Squibb/BMS) [Prescribing Information]
Reference
[1] Tawbi HA, Hodi FS, Lipson EJ, et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. J Clin Oncol. 2023;41:16s (suppl; abstr 9502).
[2] Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. PMID: 35403841; PMCID: PMC9844511.
[3] Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. PMID: 38749033.
Featured image courtesy: © 2016 – 2024 ASCO/Nick Agro 2023. Used with permission.
, to be held May 31st - June 4th, 2024, expect to see major presentation of data across Bristol Myers Squibb (BMS)'s oncology and hematology portfolio including data from more than 130 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning approximately 25 cancer types and serious blood disorders.){kind=link}